Gentium wins orphan drug status for liver therapy

Italy's Gentium has won orphan drug status for its lead drug candidate, Defibrotide. The drug is intended to treat the damage done by radiation therapy to blood vessel cells, when small veins in the liver are blocked. That condition can cause liver failure. The drug is in Phase III.

- check out the release
- here's the AP's report on Gentium

Related Article:
Gentium acquires Italian Defibrotide rights from Crinos. Release